LEADING THE RAS RENAISSANCE
ABOUT
MORE THAN
30%
OF ALL HUMAN
CANCERS ARE DRIVEN
BY MUTATIONS OF
RAS GENES
RAS MUTATIONS
In HUMAN CANCERS
PANCREAS - KRAS 95%
COLORECTAL - KRAS 45%
LUNG - KRAS 35%
AML - NRAS 30%
MELANOMA - KRAS 15%
BLADDER - NRAS 15%
"RAS ONCOGENES ARE THE WORST ONCOGENES."
-Dr. Frank McCormick
RAS National Program Advisor
*There is still not a single effective inhibitor in the clinic that directly targets Ras
xRas
Therapeutics
Year
Established
2016
Recombinant
Human
Antibodies
18
Different Ras
Mutations
Targeting
We are engineering recombinant human antibodies capable of penetrating the cell and recognizing the mutated forms of the Ras oncoprotein. These antibodies block the downstream oncogenic signaling of Ras that causes cancer resulting in senescence of the tumor cell.
Here are pancreatic cancer cells (MIA PaCa-2) under a microscope over the course of several days. Notice the rapid growth and uncontrolled proliferation.
Here are the same pancreatic cancer cells after a single treatment with an xRas antibody. The green dye is an indicator of cell death.
xRAS TECHNOLOGY
NEWS
1.16 xRas Therapeutics named 2016 Semi-Finalists for the OneStart Global Life Science Competition Link 1 Link 2
4.16 UCSF announces Paul Marinec, Ph.D. is one of four Spring 2016 Catalyst Awardees for Therapeutics Link
6.16 The UCSF Clinical & Translational Science Institute features Paul Marinec, Ph.D. and xRas technology in a news release Link
TEAM
Paul Stephen Marinec, Ph.D.
Co-Founder
Expert in phage display
& antibody engineering
Anthony Baldor, MBA
Co-Founder
Experienced biotech entrepreneur
CONTACT
Inquiries
For any inquiries, questions or commendations, please fill out the following form:
Headquarters
